Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRTA 
Prothena Corporation plc (PRTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: PRTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.41% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 307.89M USD | Price to earnings Ratio - | 1Y Target Price 24.29 |
Price to earnings Ratio - | 1Y Target Price 24.29 | ||
Volume (30-day avg) 2217270 | Beta -0.08 | 52 Weeks Range 4.32 - 25.42 | Updated Date 06/22/2025 |
52 Weeks Range 4.32 - 25.42 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.94% | Operating Margin (TTM) -2318.99% |
Management Effectiveness
Return on Assets (TTM) -15.49% | Return on Equity (TTM) -23.46% |
Valuation
Trailing PE - | Forward PE 64.1 | Enterprise Value -99841663 | Price to Sales(TTM) 2.23 |
Enterprise Value -99841663 | Price to Sales(TTM) 2.23 | ||
Enterprise Value to Revenue 2.82 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53827000 | Shares Floating 40657673 |
Shares Outstanding 53827000 | Shares Floating 40657673 | ||
Percent Insiders 19.01 | Percent Institutions 74.26 |
Analyst Ratings
Rating 4.3 | Target Price 49 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prothena Corporation plc
Company Overview
History and Background
Prothena Corporation plc is a late-stage clinical biotechnology company headquartered in Dublin, Ireland, focused on developing novel therapies for neurodegenerative diseases. Founded in 2012 from Elan Corporation's neurodegenerative disease programs, Prothena's initial focus was on Alzheimer's disease and Parkinson's disease. Significant milestones include advancing several clinical-stage programs and securing partnerships with major pharmaceutical companies.
Core Business Areas
- Neurodegenerative Diseases: Development of therapies for diseases like Alzheimer's, Parkinson's, and ATTR amyloidosis.
Leadership and Structure
The leadership team includes a CEO, CFO, and CMO, along with a board of directors. The organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- PRX012 (Alzheimer's Disease): An investigational subcutaneous antibody targeting amyloid beta for the treatment of Alzheimer's disease. Market share is currently 0% as it is in clinical trials. Competitors include Biogen (ADUHELM), Eisai (LEQEMBI), and Eli Lilly (donanemab pending approval).
- Birtamimab (ATTR Amyloidosis): An investigational antibody designed to neutralize soluble amyloid aggregates. Market share is currently 0% as it is in clinical trials. Competitors include Alnylam Pharmaceuticals (ONPATTRO, AMVUTTRA), Ionis Pharmaceuticals (TEGSEDI), and Pfizer (VYNDAQEL, VINDAMAX).
Market Dynamics
Industry Overview
The biotechnology industry, specifically focused on neurodegenerative diseases, is characterized by high risk, high reward, and significant unmet medical need. Increasing aging populations drive demand for effective therapies.
Positioning
Prothena is positioned as a leader in developing innovative antibody-based therapies for neurodegenerative diseases, focusing on novel targets and mechanisms of action. Its competitive advantage lies in its scientific expertise and clinical development capabilities.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease and ATTR amyloidosis is estimated to be in the tens of billions of dollars. Prothena is positioned to capture a significant share of this market if its clinical programs are successful.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Strong scientific expertise
- Clinical development capabilities
- Strategic partnerships
Weaknesses
- High clinical trial risk
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Small market capitalization
Opportunities
- Potential for breakthrough therapies
- Growing demand for neurodegenerative disease treatments
- Expansion into new therapeutic areas
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biotechnology and pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- BIIB
- ESAI
- LLY
- ALNY
- PFE
Competitive Landscape
Prothena competes with both large pharmaceutical companies and other biotechnology companies in the neurodegenerative disease space. Its advantages include novel therapeutic targets and scientific expertise. Its disadvantages include limited financial resources and high clinical trial risk.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the clinical pipeline and securing partnership agreements.
Future Projections: Future growth depends on the success of clinical trials and potential regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing PRX012 and Birtamimab through clinical trials and exploring new therapeutic targets.
Summary
Prothena is a high-risk, high-reward biotechnology company focused on developing therapies for neurodegenerative diseases. Success hinges on positive clinical trial outcomes, particularly for PRX012 and Birtamimab. The company's innovative approach to novel targets gives it an advantage, but financial constraints and regulatory hurdles pose significant challenges. Prothena's market position is dependent on successful late-stage trials leading to FDA approval.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Prothena Corporation plc Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made with the advice of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.prothena.com |
Full time employees 163 | Website https://www.prothena.com | ||
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.